Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotic Disorders | 2 | 2020 | 151 | 1.150 |
Why?
|
| Medication Adherence | 2 | 2019 | 561 | 0.890 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2104 | 0.830 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 155 | 0.710 |
Why?
|
| Social Support | 1 | 2024 | 587 | 0.690 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 84 | 0.660 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 618 | 0.650 |
Why?
|
| Indians, North American | 1 | 2023 | 601 | 0.550 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 236 | 0.540 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 1023 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 903 | 0.420 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2018 | 130 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1560 | 0.350 |
Why?
|
| Mental Disorders | 1 | 2018 | 1035 | 0.330 |
Why?
|
| SEER Program | 2 | 2019 | 202 | 0.290 |
Why?
|
| Thromboembolism | 2 | 2018 | 112 | 0.250 |
Why?
|
| Pandemics | 2 | 2024 | 1500 | 0.240 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 5085 | 0.200 |
Why?
|
| Aged | 5 | 2024 | 22107 | 0.200 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2019 | 26 | 0.200 |
Why?
|
| United States | 4 | 2024 | 13913 | 0.180 |
Why?
|
| International Classification of Diseases | 2 | 2018 | 122 | 0.170 |
Why?
|
| Medicare Part D | 1 | 2019 | 26 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 109 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 7066 | 0.150 |
Why?
|
| Breast | 1 | 2019 | 140 | 0.150 |
Why?
|
| Mastectomy | 1 | 2019 | 132 | 0.150 |
Why?
|
| Drug Costs | 1 | 2019 | 100 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 377 | 0.150 |
Why?
|
| Mental Health | 1 | 2024 | 691 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2019 | 180 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 62 | 0.140 |
Why?
|
| Medical Records | 1 | 2018 | 171 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 422 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2018 | 1269 | 0.120 |
Why?
|
| Female | 6 | 2024 | 68829 | 0.120 |
Why?
|
| Comorbidity | 1 | 2019 | 1551 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 287 | 0.110 |
Why?
|
| Humans | 8 | 2024 | 129847 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 719 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2019 | 14553 | 0.090 |
Why?
|
| Hospitalization | 2 | 2018 | 2079 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 1021 | 0.090 |
Why?
|
| Young Adult | 2 | 2024 | 12467 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2018 | 5444 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 31177 | 0.070 |
Why?
|
| Adult | 2 | 2024 | 35634 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1951 | 0.050 |
Why?
|
| Male | 3 | 2024 | 63759 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2018 | 979 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2018 | 21 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2018 | 20 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 176 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 212 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 428 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1368 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 3089 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3269 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 5772 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 9018 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 10522 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 20451 | 0.010 |
Why?
|
| Child | 1 | 2018 | 20962 | 0.010 |
Why?
|